Search Results - "Pharmacogenetics"
Suggested Topics within your search.
Suggested Topics within your search.
- Drug development
- Pharmacogenetics 22
- Drug Discovery 21
- Drugs 15
- drug therapy 15
- Cancer 12
- Pharmaceutical Preparations 12
- metabolism 12
- methods 12
- pharmacology 12
- Antibacterial agents 9
- Antitubercular Agents 9
- Arylamine N-Acetyltransferase 9
- Bacterial Infections 9
- Biochemical markers 9
- Biomarkers 9
- Breast 9
- Breast Neoplasms 9
- Enzyme Inhibitors 9
- Ethnic Groups 9
- Gene Expression Regulation, Enzymologic 9
- Genetic Association Studies 9
- Isoenzymes 9
- Metabolism 9
- Mice, Transgenic 9
- Mycobacterium 9
- Pharmacogenomics 9
- Precision Medicine 9
- Transferases 9
- antagonists & inhibitors 9
-
1
Establishing precompetitive collaborations to stimulate genomics-driven product development workshop summary /
Published 2011Subjects: “…Pharmacogenetics Congresses.…”
An electronic book accessible through the World Wide Web; click to view
Electronic Conference Proceeding eBook -
2
Pharmacogenomics emphasis on clinical drug development /
Published 2012Subjects: Get full text
Series
Electronic Video -
3
-
4
Pharmacogenomics emphasis on clinical drug development /
Published 2012Subjects: Get full text
Series
Electronic Video -
5
Pharmacogenomics emphasis on clinical drug development /
Published 2012Subjects: Get full text
Series
Electronic Video -
6
-
7
-
8
Key drug discovery challenges in cardiovascular medicine
Published 2014Table of Contents: “…Contents: Conventional therapeutic targets in CVD -- Identifying new targets (GWAS and association analysis) -- Validating new targets (Mendelian randomisation; IL6R, CHD and tocilizumab; sPLA2 inhibition and CHD prevention) -- Avoiding adverse effects (The ILLUMINATE trial, Torcetrapib and blood pressure) -- Making better use of existing drugs (Pharmacogenetics of Clopidogrel and CYP2C19) -- New approaches & drug development.…”
Get full text
Series (Genetics of cardiovascular disease)
Series (Small molecule drug discovery)
Electronic Video -
9
Overview of clinical pharmacology in cancer part 1 of 2 /
Published 2017Subjects: Get full text
Series
Electronic Video -
10
Key drug discovery challenges in cardiovascular medicine
Published 2014Table of Contents: “…Contents: Conventional therapeutic targets in CVD -- Identifying new targets (GWAS and association analysis) -- Validating new targets (Mendelian randomisation; IL6R, CHD and tocilizumab; sPLA2 inhibition and CHD prevention) -- Avoiding adverse effects (The ILLUMINATE trial, Torcetrapib and blood pressure) -- Making better use of existing drugs (Pharmacogenetics of Clopidogrel and CYP2C19) -- New approaches & drug development.…”
Get full text
Series (Genetics of cardiovascular disease)
Series (Small molecule drug discovery)
Electronic Video -
11
Key drug discovery challenges in cardiovascular medicine
Published 2014Table of Contents: “…Contents: Conventional therapeutic targets in CVD -- Identifying new targets (GWAS and association analysis) -- Validating new targets (Mendelian randomisation; IL6R, CHD and tocilizumab; sPLA2 inhibition and CHD prevention) -- Avoiding adverse effects (The ILLUMINATE trial, Torcetrapib and blood pressure) -- Making better use of existing drugs (Pharmacogenetics of Clopidogrel and CYP2C19) -- New approaches & drug development.…”
Get full text
Series (Genetics of cardiovascular disease)
Series (Small molecule drug discovery)
Electronic Video -
12
Overview of clinical pharmacology in cancer part 1 of 2 /
Published 2017Subjects: Get full text
Series
Electronic Video -
13
Overview of clinical pharmacology in cancer part 1 of 2 /
Published 2017Subjects: Get full text
Series
Electronic Video -
14
Arylamine N-acetyltransferases part 2 of 3 /
Published 2016Table of Contents: “…Contents: Mechanism of action -- Reaction substrates -- Isoform substrate profiles -- Isoenzymes NAT1 and NAT2 -- Regulation of gene expression -- Pharmacogenetics -- Phenotype/genotype correlation -- Ethnic variation -- Transgenic mouse models -- NAT protein structures -- NAT as a biomarker in breast cancer -- NAT inhibitors as diagnostic agents -- NAT in mycobacteria -- NAT inhibitors as an approach to potential anti-tubercular agents.…”
Get full text
Series
Electronic Video -
15
Arylamine N-acetyltransferases part 3 of 3 /
Published 2016Table of Contents: “…Contents: Mechanism of action -- Reaction substrates -- Isoform substrate profiles -- Isoenzymes NAT1 and NAT2 -- Regulation of gene expression -- Pharmacogenetics -- Phenotype/genotype correlation -- Ethnic variation -- Transgenic mouse models -- NAT protein structures -- NAT as a biomarker in breast cancer -- NAT inhibitors as diagnostic agents -- NAT in mycobacteria -- NAT inhibitors as an approach to potential anti-tubercular agents.…”
Get full text
Series
Electronic Video -
16
Arylamine N-acetyltransferases part 1 of 3 /
Published 2016Table of Contents: “…Contents: Mechanism of action -- Reaction substrates -- Isoform substrate profiles -- Isoenzymes NAT1 and NAT2 -- Regulation of gene expression -- Pharmacogenetics -- Phenotype/genotype correlation -- Ethnic variation -- Transgenic mouse models -- NAT protein structures -- NAT as a biomarker in breast cancer -- NAT inhibitors as diagnostic agents -- NAT in mycobacteria -- NAT inhibitors as an approach to potential anti-tubercular agents.…”
Get full text
Series
Electronic Video -
17
Arylamine N-acetyltransferases part 2 of 3 /
Published 2016Table of Contents: “…Contents: Mechanism of action -- Reaction substrates -- Isoform substrate profiles -- Isoenzymes NAT1 and NAT2 -- Regulation of gene expression -- Pharmacogenetics -- Phenotype/genotype correlation -- Ethnic variation -- Transgenic mouse models -- NAT protein structures -- NAT as a biomarker in breast cancer -- NAT inhibitors as diagnostic agents -- NAT in mycobacteria -- NAT inhibitors as an approach to potential anti-tubercular agents.…”
Get full text
Series
Electronic Video -
18
Arylamine N-acetyltransferases part 3 of 3 /
Published 2016Table of Contents: “…Contents: Mechanism of action -- Reaction substrates -- Isoform substrate profiles -- Isoenzymes NAT1 and NAT2 -- Regulation of gene expression -- Pharmacogenetics -- Phenotype/genotype correlation -- Ethnic variation -- Transgenic mouse models -- NAT protein structures -- NAT as a biomarker in breast cancer -- NAT inhibitors as diagnostic agents -- NAT in mycobacteria -- NAT inhibitors as an approach to potential anti-tubercular agents.…”
Get full text
Series
Electronic Video -
19
Arylamine N-acetyltransferases part 1 of 3 /
Published 2016Table of Contents: “…Contents: Mechanism of action -- Reaction substrates -- Isoform substrate profiles -- Isoenzymes NAT1 and NAT2 -- Regulation of gene expression -- Pharmacogenetics -- Phenotype/genotype correlation -- Ethnic variation -- Transgenic mouse models -- NAT protein structures -- NAT as a biomarker in breast cancer -- NAT inhibitors as diagnostic agents -- NAT in mycobacteria -- NAT inhibitors as an approach to potential anti-tubercular agents.…”
Get full text
Series
Electronic Video -
20
Arylamine N-acetyltransferases part 2 of 3 /
Published 2016Table of Contents: “…Contents: Mechanism of action -- Reaction substrates -- Isoform substrate profiles -- Isoenzymes NAT1 and NAT2 -- Regulation of gene expression -- Pharmacogenetics -- Phenotype/genotype correlation -- Ethnic variation -- Transgenic mouse models -- NAT protein structures -- NAT as a biomarker in breast cancer -- NAT inhibitors as diagnostic agents -- NAT in mycobacteria -- NAT inhibitors as an approach to potential anti-tubercular agents.…”
Get full text
Series
Electronic Video